N/A N=44

Physiologic Effect of Topical Nitroglycerin on Microcirculation Capacity in Patients With Circulatory Shock.

Circulatory Shock · Cardiovascular Shock

Bottom Line

View on ClinicalTrials.gov: NCT05102734 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2024

Primary outcome: Primary: Perfused Vessel Density (PVD) — 24.81; 20.44; 26.41; 21.88 mm/mm^2

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: Nitroglycerin Topical Product (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Pennsylvania
Primary completion: Feb 2022

Outcome Measures

Outcome	Result	p-value
PRIMARY Perfused Vessel Density (PVD)	24.81; 20.44; 26.41; 21.88	—
SECONDARY Mean Arterial Pressure	95.85; 71.05; 70.35; 74.4	—
SECONDARY Cardiac Index	2.54; 2.85; 2.88; 2.83	—
SECONDARY Central Venous Pressure	16.7; 9.35; 9.15; 9.16	—

Summary

This is an open-label, single center, trial that will enroll up to 25 participants with circulatory shock after cardiac surgery. Participants will be administered a topical sublingual nitroglycerin solution and assessed for changes microcirculatory blood flow using incident dark field microscopy.

Eligibility Criteria

Inclusion Criteria

Adult patients receiving elective CABG or valvular surgery requiring cardiopulmonary bypass
Receiving postoperative catecholamine therapy to maintain a MAP > 65mmHg, cardiac index > 2 despite initial fluid resuscitation
Invasive hemodynamic monitoring

Exclusion Criteria

Surgical hemorrhage
Unable to tolerate sublingual microcirculatory flow imaging
Known intolerance or allergy to nitroglycerin
Inadequate microcirculation imaging (based on Massey Score)

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05102734). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.